Strain Information | |
---|---|
Image | |
BRC No. | RBRC09896 |
Type | Targeted Mutation![]() |
Species | Mus musculus |
Strain name | B6.129P2-Cdh17<tm1Ohn> |
Former Common name | CDH17 KO |
H-2 Haplotype | |
ES Cell line | E14.1 [129P2/OlaHsd] |
Background strain | C57BL/6JJcl |
Appearance | |
Strain development | Developed by Drs. Takeyuki Shimizu, Kazuo Ohnishi and Fritz Melchers. E14.1 ES cells derived from 129P2/OlaHsd were used. C57BL/6 congenic strain by backcrossing to C57BL/6J for 10 generations. |
Strain description | Cdh17 knockout mice. Exons 16-18 were replaced with a neomycin resistance cassette. |
Colony maintenance | |
References | Lymphocyte-expressed BILL-cadherin/cadherin-17 contributes to the development of B cells at two stages. Ohnishi K, Melchers F, Shimizu T J. Immunol., 35, 957-963 (2005). 15688343BILL-cadherin/cadherin-17 contributes to the survival of memory B cells. Funakoshi S, Shimizu T, Numata O, Ato M, Melchers F, Ohnishi K PLoS One, 10(1): e0117566 (2015). 25612318 |
Health Report | |
---|---|
Examination Date / Room / Rack |
Gene | |||||||
---|---|---|---|---|---|---|---|
Gene Symbol | Gene Name | Chr. | Allele Symbol | Allele Name | Common Names | Promoter | Diseases Related to This Gene |
Cdh17 MGI:1095414 | cadherin 17 | 4 | Cdh17<tm1Ohn> MGI:3573870 | targeted mutation 1, Kazuo Ohnishi | |||
neo | neomycin resistance gene (E. coli) | 4 | herpes simplex virus thymidine kinase promoter (HSV tk promoter) |
Phenotype | |
---|---|
Annotation by Mammalian phenotyhpe ontology | more 7 phenotypes |
Detailed phenotype data |
Ordering Information | |
---|---|
Donor DNA | herpes simplex virus thymidine kinase promoter (HSV tk promoter), E. coli neo, mouse Cdh17 genomic DNA |
Research application | Immunology and Inflammation Research |
Specific Term and Conditions | Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. J. Immunol., 35, 957-963 (2005). PLoS One, 10(1):e0117566 (2015). For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE |
Depositor | Kazuo Ohnishi (National Institute of Infectious Diseases) |
Strain Status | ![]() ![]() |
Strain Availability | Recovered litters from cryopreserved embryos (2 to 4 months) Cryopreserved sperm (within 1 month) Cryopreserved embryos (within 1 month) |
Additional Info. | Necessary documents for ordering:
Genotyping protocol -PCR- |
BRC mice in Publications |
---|
No Data |